AI adoption in life sciences stalls when teams buy AI as a capability instead of attaching it to a decision someone already owns. The model may be strong. The demo may be clean. But if the tool does not change a workflow, improve a specific decision, and keep a human accountable for the outcome, it becomes another system people admire briefly and then work around.
That is the difference between AI that is installed and AI that is absorbed.
Key takeaways
- AI projects usually stall because of workflow, data, and ownership gaps, not because the underlying model is too weak.
- Life sciences teams need AI tied to specific commercial, clinical, or operational decisions, not broad mandates to "use AI."
- Human oversight is not a concession. In regulated work, it is the operating model.
- Explainability has to include uncertainty and failure modes, not just confident answers.
- The best vendor question is not "how accurate is it?" It is "what decision does this improve, who owns that decision, and can we inspect the reasoning?"
Why is the adoption gap still real?
Walk into almost any biotech, CDMO, CRO, or pharma commercial organization in 2026 and you will find AI somewhere. A tool here. A pilot there. A vendor contract signed last quarter. What you will find far less often is AI that has changed how decisions get made.
That gap is the real story of AI in life sciences right now.
McKinsey's 2025 State of AI report found that 88% of organizations use AI in at least one business function, yet adoption is not the same as operational impact. Gartner has warned that through 2026, organizations will abandon 60% of AI projects unsupported by AI-ready data. Forbes, citing MIT research, reported that 95% of generative AI pilots fail to create meaningful business impact when organizations avoid the hard workflow change underneath the technology.
Read those together and the pattern is hard to miss. The blocker is rarely just the model. It is the data the model sits on, the process it is supposed to enter, the decision it is supposed to improve, and the person who remains accountable for what it produces.
I have spent more than a decade around life sciences commercial work before building LuminOne, and I now spend most of my week with leaders who are confronting this exact gap. The conversation is rarely "which AI should we buy?" The more honest version is: "we bought the AI, and not much changed."
One conference line has stayed with me because it captured the divide clearly: some organizations treat AI as something to lean on, while others use it to see further. The technology can be identical. The operating posture is not.
Why do AI projects fail in life sciences?
AI projects in life sciences usually fail for organizational and structural reasons before they fail for technical ones. Five causes account for most stalled pilots.
AI is adopted as a capability to own
When the goal is "we need an AI strategy," the tool enters the building as a product to display, not as a fix for a decision that is currently going badly. Nothing around the tool is forced to change, so nothing does.
The better starting point is concrete: a pipeline review built on stale numbers, a field team buried under account signals, a site-selection process relying on instinct, or a commercial leader trying to understand which relationship changed and why.
The data underneath is not ready
Life sciences data often sits across validated systems, CRM fields, meeting notes, market feeds, documents, email, calendar context, and partner systems. It carries the scars of acquisitions, custom workflows, and fragmented ownership.
AI does not make that mess disappear. It exposes it.
Without reliable data quality, lineage, and context, even a strong model can produce output that looks confident but cannot be trusted. This is why AI-ready data is not a technical hygiene issue. It is a commercial operating issue.
No human owns the output
When an AI surfaces a recommendation and no specific person is answerable for acting on it, the recommendation gets noticed, discussed, and quietly filed away.
AI without an accountable owner becomes decoration.
The tool does not fit the workflow
Every trial, territory, therapeutic area, account plan, and revenue motion has local nuance. A generic system that asks the workflow to bend around it loses to the workflow every time.
In life sciences, workflow fit is not polish. It is survival.
Trust was never earned
A model that gives an answer without showing the reasoning, the supporting evidence, or its own uncertainty will not be used for decisions that matter. It may be used for drafts, summaries, and low-risk tasks. But it will not become part of the operating rhythm.
None of this is a reason to avoid AI. It is a reason to adopt it differently.
What should life sciences teams do instead?
Life sciences teams should start from the decision, not from the technology. The useful question is not "should we bring AI into the business?" The useful question is: "what important decision is slow, stale, inconsistent, or overloaded, and what would make that decision better?"
Only after that should the team ask whether AI can accelerate the answer.
That distinction changes everything. When AI is tied to a decision a person owns, the surrounding workflow has to change for the tool to matter. When AI is bought as a broad capability, there is no pressure on the operating system around it.
This also changes what "good AI" means in a regulated industry. It is not the flashiest interface. It is not the highest benchmark score in isolation. It is the system that understands the workflow it enters, improves a decision that matters, and makes its reasoning available to the human who owns the outcome.
What does accountable AI require?
Accountable AI requires a human decision owner, inspectable reasoning, and a clear boundary between prepared work and approved action.
In life sciences, AI cannot be a black box that quietly makes the call. The model can prepare work. It can correlate signals. It can draft the next action. It can surface what changed in an account, a trial, a market, or a relationship. But a human has to be able to inspect the reasoning and answer for the decision.
This is now aligned with the direction of regulators. The FDA's January 2025 draft guidance on artificial intelligence to support regulatory decision-making for drugs and biological products emphasized credibility, risk, and sponsor responsibility. FDA's work with EMA on Good AI Practice principles for drug development also points toward a human-centric, risk-based posture for AI across the drug lifecycle.
The practical translation is simple: the model can do work, but responsibility does not move.
AI that improves human judgment is an asset. AI that quietly replaces human judgment in regulated contexts is a liability waiting for an audit.
How should leaders evaluate AI vendors?
Most vendor evaluations start with accuracy. Accuracy matters, but it is too narrow to be the first question. In life sciences, the stronger evaluation starts with seven operating questions.
What specific decision does this improve?
If the answer is "it analyzes data," keep pushing. If the answer is "it tells the field team which accounts need attention this week, why those accounts moved, and what work is ready for review," you are closer to the right level of specificity.
Can it explain uncertainty and errors?
A vendor will usually talk about where the model is right. The more revealing question is what happens when the model is wrong or unsure.
A useful system can expose the evidence, show the reasoning path, and flag uncertainty. A system that is quietly confident most of the time is still a black box.
Who owns the output?
There should be a clear answer to which person owns the decision the AI informs. If there is no owner, the project has an accountability gap before it starts.
Does it fit the workflow we already run?
Ask to see the system inside a workflow that looks like yours. Life sciences teams do not need another destination app that gets checked when someone remembers. They need intelligence that enters the places where work already happens.
Is it built on data we can trust?
Ask how the vendor handles quality, lineage, provenance, permissions, validation realities, and fragmented context. The model is only as reliable as the data and workflow context beneath it.
Does it support human oversight?
The vendor should be able to explain human-in-the-loop design without treating it as a compliance afterthought. Approval should be part of the product architecture, not a paragraph in the security review.
What concrete incentive does it create?
If a tool does not shorten a cycle, reduce manual drag, increase decision quality, or remove friction a team feels every week, it will lose to everything else competing for attention.
What does this look like when it works?
The organizations crossing the adoption gap do not begin with "we need an AI strategy." They start with a decision that is going badly today.
They tie AI to that decision. They assign a human owner. They demand reasoning. They measure whether the work changes.
That is the principle behind what we are building at LuminOne with ARIA, the autonomous intelligence layer for life sciences commercial organizations. ARIA is not designed to be another AI tool sitting beside the CRM that no one opens twice. She is designed to correlate signals across the commercial organization, surface what matters, and prepare completed work for a human to approve, with the reasoning visible.
The bar is not "here is an accurate AI tool."
The bar is "here is a problem you already have, here is the work prepared against it, here is the evidence, here is where the system is uncertain, and here is the human who approves what happens next."
That is the difference between AI as a purchase and AI as an operating layer.
Sources
- McKinsey, The State of AI
- Gartner, Lack of AI-Ready Data Puts AI Projects at Risk
- Forbes, MIT Finds 95% of GenAI Pilots Fail Because Companies Avoid Friction
- FDA, Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products
- FDA, Artificial Intelligence in Drug Development
Frequently asked questions
Why do most AI projects fail in life sciences?
Most AI projects in life sciences fail for organizational and structural reasons rather than technical ones: unclear business ownership, data that is not ready for AI, weak workflow fit, missing accountability, and models that do not explain their reasoning.
What is the difference between AI adoption and AI impact?
AI adoption means the technology is present. AI impact means decisions are made differently because of it. If switching off the AI would not change a team's priorities, timing, or actions, the system has been adopted but not absorbed.
How should commercial and clinical leaders evaluate AI vendors?
Leaders should ask what specific decision the tool improves, whether the system can explain uncertainty and errors, who owns the output, whether it fits existing workflows, how it handles data quality and lineage, and whether it supports human oversight.
Why is explainability important for AI in life sciences?
Explainability matters because life sciences decisions carry regulatory, commercial, and patient-safety consequences. A system that cannot show why it reached a recommendation, or when it is uncertain, cannot be trusted for decisions that matter.
Is AI in life sciences meant to replace people?
No. The strongest use of AI in life sciences improves human judgment rather than replacing it. The model can prepare work, surface reasoning, and compress analysis, but accountability stays with a human decision owner.
What does accountable AI mean in practice?
Accountable AI means a named human owns the decision the AI informs, can inspect the reasoning behind the output, and remains responsible for what happens next.
Dhruv Patwardhan is the founder and CEO of LuminOne, where he is building ARIA, the autonomous intelligence layer for life sciences commercial organizations. He spent more than a decade in and around commercial operations before founding the company.
Building or evaluating AI for a life sciences commercial team? Learn more about ARIA or connect with Dhruv on LinkedIn.